We aimed to investigate whether CYP2D6 polymorphisms were associated with the intraocular pressure (IOP)-lowering effect and systemic complications (especially bradycardia) of ophthalmic timolol.
According to SNP genotyping in 73 subjects, there was no significant difference of IOP between subjects with different CYP2D6Arg296Cys (P = 0.308) or Ser486Thr genotypes (P = 0.741).
To determine whether candidate pharmacodynamic (beta-adrenergic receptor) and pharmacokinetic (cytochrome P450 2D6) gene polymorphisms are associated with the intraocular pressure (IOP) response to topical beta-blockers.